-

Segal Trials Showcased Leadership in CNS Research and Psychedelic Studies at CNS Summit 2023

MIAMI--(BUSINESS WIRE)--Segal Trials, a pioneering clinical research site network, is proud to announce its participation in this year’s CNS Summit that occurred in Boston, MA on November 8-11, 2023, a one of a kind event in the life sciences industry. As a founding member of CNS Summit since 2010, Segal Trials continues to make a significant impact in central nervous system (CNS) research and remains at the forefront of cutting-edge psychedelic science.

CNS Summit 2023 was an unparalleled gathering of industry leaders, providing a platform to discuss the latest advancements in the field and network with a curated community of visionaries. With a diverse array of sessions covering topics crucial to the life sciences industry, this is a "must-go-to" event for anyone invested in advancing medicine and driving positive change.

As a proud panelist in the Psychedelic Spotlight Session at the Summit, Dr. Rishi Kakar, Medical Director and CSO at Segal Trials, emphasized the importance of having the site's voice heard, stating, "In the evolving landscape of CNS research, psychedelic studies have emerged as a promising frontier. At Segal Trials, we are dedicated to pushing the boundaries of scientific exploration and unlocking the potential of psychedelic treatments. Participating in CNS Summit 2023 allows us to share our insights and contribute to the global conversation on psychedelic research."

Amir Kalali, Chief Curator and Chairman of CNS Summit, shared his mission behind the event, saying, "CNS Summit is a platform for collaboration, innovation, and transformative discussions that drive progress in the life sciences industry. We are thrilled to have Segal Trials as a long-standing partner and advocate for pioneering research."

As one of the first private research sites to conduct psychedelic clinical studies in the US, Segal Trials continues to reinforce its position as a leading research site network.

For more information about Segal Trials and their participation in CNS Summit 2023, please visit www.SegalTrials.com

About Segal Trials:

Established in 1999, Segal Trials is a leading clinical research site network dedicated to advancing medical science and improving the lives of patients through high-quality research. With a focus on central nervous system disorders, women’s health and infectious disease, Segal Trials plays a pivotal role in shaping the future of medicine.

Contacts

Media Contact
Tabatha Cirgenski, Director of Marketing
Segal Trials
tcirgenski@segaltrials.com
305-722-8444

Industry:

Segal Trials

Release Versions
English

Contacts

Media Contact
Tabatha Cirgenski, Director of Marketing
Segal Trials
tcirgenski@segaltrials.com
305-722-8444

More News From Segal Trials

Segal Trials Participates in Research Leading to FDA Approval of Tonmya™, the First New Fibromyalgia Treatment in More Than 16 Years

MIAMI LAKES, Fla.--(BUSINESS WIRE)--Segal Trials announced its participation as a clinical research site in the pivotal studies that supported the U.S. Food and Drug Administration’s (FDA) approval of Tonmya™ (cyclobenzaprine HCl sublingual tablets) for the treatment of fibromyalgia in adults. This milestone, announced by Tonix Pharmaceuticals, marks the first new FDA-approved therapy for fibromyalgia in more than 16 years. Dr. Olga Lapeyra, Principal Investigator at Segal Trials, provided lead...

Segal Trials Contributes to Breakthrough Flu Prevention Study Led by Cidara Therapeutics

MIAMI LAKES, Fla.--(BUSINESS WIRE)--Segal Trials proudly announces its participation in the successful Phase 2b NAVIGATE clinical trial conducted by Cidara Therapeutics, evaluating CD388—a novel, non-vaccine, long-acting antiviral—for the prevention of seasonal influenza. Dr. Steven Chavoustie served as the Principal Investigator for the study at Segal Trials. The NAVIGATE trial enrolled over 5,000 healthy, unvaccinated adults and met both its primary and secondary efficacy endpoints, showing t...

Segal Trials Investigator Dr. Olga Lapeyra Contributes to Pivotal Migraine Study Leading to FDA Approval of Atzumi™

MIAMI--(BUSINESS WIRE)--Segal Trials, a South Florida-based clinical research network specializing in psychiatric and neurological disorders, is proud to recognize the contributions of Dr. Olga Lapeyra to the successful Satsuma Pharmaceuticals Phase 3 clinical trial evaluating Atzumi™ (dihydroergotamine nasal powder), recently approved by the U.S. Food and Drug Administration (FDA) for the acute treatment of migraine with or without aura in adults. As a principal investigator at Segal Trials, D...
Back to Newsroom